1. United Kingdom Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
NIOX Group Plc

NIOX Group Plc

67.80
GBX
+1.80
(+2.73%)
27.75BMarket Cap
Mar 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.04
0.08
0.14
0.14
0.09
0.06
0.07
0.07
0.09
0.1
0.12
- -
Basic EPS, GAAP
-0.11
-0.21
-0.2
-0.48
-0.31
-0.34
-0.13
-0.09
0.01
0.04
0.03
0.01
0.02
- -
Free Cash Flow per Basic Share
-0.1
-0.22
-0.22
-0.2
-0.18
-0.12
-0.09
-0.06
- -
0.02
0.03
0.04
0.03
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.01
0.01
- -
Book Value per Share
0.16
1.01
1.43
0.99
0.67
0.35
0.23
0.17
0.16
0.2
0.2
0.15
0.16
0.16
Tangible Book Value per Share
0.15
1
0.57
0.36
0.05
-0.29
-0.22
0.04
0.06
0.11
0.12
0.08
0.09
0.09
Basic Weighted Avg Shares
187
169
250
285
320
344
374
382
413
419
420
418
414
415
Sales/Revenue/Turnover
- -
- -
11
23
46
48
35
24
28
31
37
42
49
- -
Operating Margin (%)
- -
- -
-625
-189.61
-177.75
-77.02
-184.39
-72.38
-12.9
5.75
12.5
18.42
21.97
- -
Depreciation Expense
- -
- -
3
5
5
4
15
9
5
5
4
4
4
- -
Net Income, GAAP
-20
-35
-50
-137
-99
-117
-48
-33
4
16
11
4
7
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
56.41
37.5
- -
Profit Margin (%)
- -
- -
-462.04
-594.37
-214.04
-242.44
-139.6
-140.17
12.9
51.44
29.08
8.85
14.37
- -
Working Capital
28
188
175
117
59
-70
7
3
9
22
26
13
23
23
LT Debt
- -
- -
- -
- -
- -
- -
111
1
1
- -
1
1
1
1
Total Equity
30
191
410
281
225
126
85
66
67
82
84
60
68
68
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.55
10.09
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.13
10.8
- -
Return on Common Equity (%)
-50
-31.79
-16.65
-39.84
-39.21
-66.78
-45.85
-44.4
5.42
21.65
12.91
5.16
11.01
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
398
398
418
Market Capitalization
251
271
277

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
21
22
31
Cash, Cash Equivalents & STI
11
12
20
Accounts Receivable, Net
5
6
4
Inventories
4
4
5
Total Current Liabilities
8
6
8
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-13.95%
2.12%
13.61%
Free Cash Flow
37.5%
89.09%
-14.2%
Net Income, GAAP
30.28%
45.34%
89.19%
Sales/Revenue/Turnover
23.6%
15.32%
16.51%
Total Cash Common Dividend
- -
- -
19.05%

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
37
2024
- -
- -
42
2025
- -
- -
49

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.03
2024
- -
- -
0.01
2025
- -
- -
0.02

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
0.01
2025
- -
- -
0.01

Company Description

Company Profile APIChatGPT
CEO
Jonathan Emms
Full Time Employees
97
Sector
Health services
Industry
Medical/Nursing services
Address
Magdalen Centre Oxford OX United Kingdom OX4 4GA
IPO Date
Mar 18, 2014
Website
niox.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
NIOX Group Plc specializes in developing and marketing medical technology globally for assessing inflammatory respiratory conditions. The company's primary offering is NIOX VERO®, a compact, user-friendly system for quantifying fractional exhaled nitric oxide (FeNO) at the point of care. This system includes a portable device along with essential consumables like sensors and disposable patient interfaces, which are crucial for accurately measuring FeNO levels in individuals. Known previously as Circassia Group Plc, the company adopted its current name in September 2022. Established in 2006, NIOX Group Plc maintains its headquarters in Oxford, United Kingdom. The firm aims to enhance asthma diagnosis and management through broader access to FeNO testing. It has reported consistent revenue growth and is developing next-generation devices, including the NIOX PRO for clinical use and the NIOX MyNO for home use.